AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11815427
Drug: Blockade of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blockade of ET(A) and ET(B) receptors using BQ-123 (100 nmol/min) and BQ-788 (50 nmol/min)
Trial: 11815427
Drug: Blockade of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blockade of ET(A/B) receptors
Trial: 12625832
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (SNP) administration
Trial: 11815427
Drug: ET-1 receptor
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ET-1 receptor antagonism
Trial: 1523288
Drug: ritanserin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ritanserin (5 mg orally)
Trial: 6337285
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1 g/day of elemental calcium)
Trial: 19614687
Drug: Carbachol (3 µg/kg)
RxNorm normalized name: Carbachol
DrugBank: Carbamoylcholine (DB00411)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbachol (3 µg/kg)
Trial: 17039266
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (cyclophosphamide, methotrexate, fluoracil)
Trial: 17039266
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (low-risk patients not on chemotherapy)
Trial: 16313543
Drug: Doubling daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling daily inhaled corticosteroid (ICS) dose (fluticasone)
Trial: 16313543
Drug: Maintaining usual
RxNorm normalized name: phenazopyridine
DrugBank: Phenazopyridine (DB01438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maintaining usual ICS dose
Trial: 16313543
Drug: Oral steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroids (OS) (dexamethasone)
Trial: 12096825
Drug: EE/DRSP (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/DRSP (30 microg ethinyl estradiol / 3 mg drospirenone)
Trial: 12096825
Drug: EE/CPA (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/CPA (35 microg ethinyl estradiol / 2 mg cyproterone acetate)
Trial: 10616770
Drug: 30mg LA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg LA once daily, 500mg AMPC tid, and 250mg MNZ tid for 2 weeks
Trial: 10616770
Drug: 30mg LA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg LA once daily, 500mg AMPC tid, and 250mg MNZ tid for 1 week
Trial: 8847197
Drug: Usual hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual hospital ward treatment with neuroleptic drugs
Trial: 1971166
Drug: Cocaine administration
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine administration (2 mg/kg body weight)
Trial: 1971166
Drug: Intracoronary propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary propranolol administration (2 mg in 5 minutes)
Trial: 1971166
Drug: Saline administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline administration (control)
Trial: 25350366
Drug: Olanzapine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5 mg/day for 7 days, then 10 mg/day for 7 days)
Trial: 24332919
Drug: Mannitol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol (0.5 g/kg) plus hydration
Trial: 17846129
Drug: Dihydroartemisinin-piperaquine (DHP)
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (DHP) treatment
Trial: 25597438
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oxycodone and pregabalin (B1 group)
Trial: 25597438
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oxycodone and pregabalin (B2 group)
Trial: 25597438
Drug: Oxycodone (A1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (A1 group)
Trial: 25597438
Drug: Oxycodone (A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (A2 group)
Trial: 19936416
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (Group D, n=42)
Trial: 19936416
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride infusion (Group P, n=39)
Trial: 3429697
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nifedipine, sublingually administered
Trial: 3429697
Drug: Chronic oral
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic oral nifedipine, 10 mg qid
Trial: 29679670
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual for 8 weeks
Trial: 22545424
Drug: Oral lornoxicam
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lornoxicam (8 mg)
Trial: 22545424
Drug: Oral paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paracetamol (500 mg)
Trial: 22545424
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (lornoxicam and paracetamol)
Trial: 18450380
Drug: Epoprostenol (PGI(2))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoprostenol (PGI(2)) infusion at 10 ng/kg/min for 25 min
Trial: 18450380
Drug: Epoprostenol (PGI(2))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoprostenol (PGI(2)) infusion
Trial: 16835477
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI regimen (CPT‐11 180 mg/m(2) as a 90‐min infusion on day 1, l‐LV 200 mg/m(2) as a 2‐h infusion during CPT‐11, followed by a bolus dose of 5‐FU 400 mg/m(2) and a 46‐h continuous infusion of 2,400 mg/m(2) every 2 weeks)
Trial: 16835477
Drug: oxaliplatin/5‐FU/LV therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin/5‐FU/LV therapy (FOLFOX)
Trial: 11737921
Drug: Activated protein
RxNorm normalized name: Activated protein C
DrugBank: Drotrecogin alfa (DB00055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated protein C and low-dose steroids in sepsis
Trial: 8442393
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dipyridamole 75 mg and acetylsalicylic acid 330 mg t.i.d.
Trial: 31347611
Drug: Gepirone extended-release
RxNorm normalized name: gepirone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepirone extended-release tablets (gepirone ER, Travivo)
Trial: 27795670
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intravenous dexamethasone (DM group)
Trial: 24413969
Drug: PCIT maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCIT maintenance treatment (MT)
Trial: 9829223
Drug: Thyroid replacement
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid replacement therapy (L-thyroxine) for 3 months
Trial: 8160095
Drug: Percutaneous radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous radiation therapy (12.5 Gy total dose over 5 days with 2.5 Gy per day)
Trial: 8160095
Drug: Stent implantation
RxNorm normalized name: castor fiber scent gland secretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stent implantation alone (no radiation therapy)
Trial: 1096537
Drug: Lithium citrate
RxNorm normalized name: Lithium Citrate
DrugBank: Lithium succinate (DB14508)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium citrate in slow release tablets
Trial: 30783682
Drug: Vatelizumab (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vatelizumab (monoclonal antibody targeting α2 subunit of VLA-2)
Trial: 26006137
Drug: Postoperative statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative statin therapy (atorvastatin 40 mg per day starting 6 hours after operation)
Trial: 26006137
Drug: Non-statin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-statin group (no postoperative statin therapy)
Trial: 26006137
Drug: Postoperative atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative atorvastatin
Trial: 21627686
Drug: Higher-dose angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose angiotensin receptor blockers
Trial: 21627686
Drug: Lower-dose angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose angiotensin receptor blockers
Trial: 19320697
Drug: Personalised Advice‐giving;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalised Advice‐giving; combination of 'Information Management' activities and 'Interactive Orientation'
Trial: 16764345
Drug: Oral levocarnitine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral levocarnitine, 3-6 g daily
Trial: 16764345
Drug: Immunosuppressive or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive or immunomodulatory therapies
Trial: 9470829
Drug: rIFN-gamma 4
RxNorm normalized name: .GAMMA.-OCTALACTONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN-gamma 4 million units (0.2 mg) subcutaneously every other day for 4 months
Trial: 9470829
Drug: Observation (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (no maintenance therapy)
Trial: 7895954
Drug: Hypoglycaemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycaemia (blood glucose 2.5 mmol/l) with 90 degrees headup posture
Trial: 7895954
Drug: Hypoglycaemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycaemia (blood glucose 2.5 mmol/l) with return to supine posture
Trial: 7895954
Drug: Hypoglycaemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycaemia (blood glucose 2.5 mmol/l) after 40 min
Trial: 7895954
Drug: Euglycaemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycaemia (blood glucose 5.0 mmol/l) using a hyperinsulinaemic clamp
Trial: 2879101
Drug: 1 microgram
RxNorm normalized name: Alfacalcidol 1 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microgram dose of Merck, Sharp and Dohme plasma vaccine
Trial: 2879101
Drug: 2 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 micrograms dose of Merck, Sharp and Dohme plasma vaccine
Trial: 2879101
Drug: Three 2
RxNorm normalized name: THREE-LOBE SAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 2 micrograms doses of vaccine
Trial: 31318424
Drug: Serologic testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serologic testing for anti-measles virus IgG antibody in a subsample of survey participants.
Trial: 22383680
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZOL) plus adjuvant systemic therapy
Trial: 22383680
Drug: Adjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant systemic therapy alone (Control)
Trial: 19269753
Drug: VAC BNO
RxNorm normalized name: VAC-52150
DrugBank: VAC-52150 (DB17781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC BNO 1095 extract (40mg herbal drug)
Trial: 16763787
Drug: Anvirzel (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anvirzel (0.1, 0.2, 0.4, 0.8, 1.2 ml/m2/day)
Trial: 12783047
Drug: C+E (Caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C+E (Caffeine 4 mg x kg‐1 + Ephedrine 0.8 mg x kg‐1)
Trial: 12783047
Drug: E (Ephedrine
RxNorm normalized name: Primatene (ephedrine hydrochloride 12.5 MG / guaifenesin 200 MG) Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E (Ephedrine 0.8 mg x kg‐1)
Trial: 12783047
Drug: C (Caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C (Caffeine 4 mg x kg‐1)
Trial: 3758239
Drug: Nebuhaler (terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebuhaler (terbutaline 0.10 mg/kg)
Trial: 3758239
Drug: Nebulizer (terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulizer (terbutaline 0.10 mg/kg)
Trial: 24089509
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment group with a 50% higher stimulated C-peptide on entry (from 0.10 to 0.15 nmol/L)
Trial: 24089509
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment group with a 50% higher stimulated C-peptide on entry
Trial: 22789125
Drug: Eltrombopag (12.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (12.5mg to 50mg daily)
Trial: 16518002
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily dosing (ODD) - 160 mg once daily
Trial: 16518002
Drug: Pharmacokinetic dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetic dosing (TCI) - 160 mg once daily initially, dose revised based on serum drug levels
Trial: 16518002
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) - 80 mg gentamicin twice daily
Trial: 12439841
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg orally twice daily on the day before and the day of contrast administration with hydration
Trial: 9719082
Drug: DFMO 0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFMO 0.20 g/m2
Trial: 9719082
Drug: DFMO 0.40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFMO 0.40 g/m2
Trial: 9719082
Drug: DFMO (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFMO (all doses)
Trial: 9719082
Drug: DFMO (0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFMO (0.20 g/m2 and 0.40 g/m2)
Trial: 4919027
Drug: Oral L-DOPA
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral L-DOPA
Trial: 4919027
Drug: Standard agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard agents
Trial: 25989732
Drug: FAHT cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAHT cream
Trial: 23884317
Drug: Distress Tolerance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distress Tolerance (DT) treatment (9 2-hr group and 6 50-min individual sessions) plus 8 weeks of transdermal nicotine patch
Trial: 23884317
Drug: Standard Smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Smoking Treatment (ST) (6 90-min group and 1 20-min individual session) plus 8 weeks of transdermal nicotine patch
Trial: 29927279
Drug: Distress Tolerance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distress Tolerance (DT) treatment
Trial: 21854342
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate delivered via dry powder inhaler (MF-DPI) 100 μg once daily in the morning (QD AM)
Trial: 21854342
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate delivered via dry powder inhaler (MF-DPI) 100 μg twice daily (BID)
Trial: 21854342
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate delivered via dry powder inhaler (MF-DPI) 200 μg once daily in the morning (QD AM)
Trial: 16567155
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein (3.6 g/kg/day)
Trial: 16567155
Drug: Moderate protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate protein (1.8 g/kg/day)
Trial: 16567155
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein (0.8 g/kg/day)
Trial: 12507714
Drug: Immediate-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release morphine given 4-hourly
Trial: 12507714
Drug: Sustained-release morphine
RxNorm normalized name: morphine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release morphine given once daily
Trial: 10844490
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg i.m.
Trial: 10844490
Drug: Diphenhydramine 50
RxNorm normalized name: diphenhydrAMINE 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 50 mg i.m.
Trial: 1625204
Drug: Cocaine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (0, 12.5, 25 and 50 mg, i.v.)
Trial: 8229755
Drug: Mazindol (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mazindol (0, 1 and 2 mg given orally 2 hr before the cocaine injection)
Trial: 30246320
Drug: Inhaled procaterol
RxNorm normalized name: procaterol
DrugBank: Procaterol (DB01366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled procaterol
Trial: 18719756
Drug: No active
RxNorm normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active treatment (control)
Trial: 10493325
Drug: Clinical pharmacist
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacist evaluation including medication evaluation, therapeutic recommendations, patient education, and follow-up telemonitoring
Trial: 1722704
Drug: Scatter photocoagulation
RxNorm normalized name: RECOMBINANT DNA DERIVED B-DOMAIN DELETED PORCINE BLOODCOAGULATION FACTOR VIII ANALOGUE, PRODUCED IN BHK21 CELLS: DES-(753-1418)-BLOOD-COAGULATION FACTOR VIII (PROCOAGULANT COMPONENT) SUS SCROFA, GLYCOSYLATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scatter photocoagulation treatment
Trial: 24465617
Drug: High-dose micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose micronutrient and anti-oxidant supplementation
Trial: 24465617
Drug: Recommended daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended daily allowance (RDA) vitamins
Trial: 18408402
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for breast cancer
Trial: 18408402
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for cervix cancers
Trial: 18408402
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for cervix pre-cancers
Trial: 11786110
Drug: LdCa (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LdCa (1.25 mmol/L)
Trial: 11786110
Drug: dCaP (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dCaP (1.25 mmol/L for first 2 hours, 1.75 mmol/L for last 2 hours)
Trial: 11786110
Drug: MdCa (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MdCa (1.5 mmol/L)
Trial: 7861833
Drug: Prophylactic amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic amphotericin B (AmB) at a dose of 0.5 mg/kg/48 h from day + 1 BMT until hemoperipheral recovery (group A)
Trial: 2683457
Drug: Oral vaccine
RxNorm normalized name: RotaTeq Oral Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vaccine (0.55 microgram active components, administered intermittently over six months)
Trial: 2683457
Drug: Oral vaccine
RxNorm normalized name: RotaTeq Oral Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vaccine (6 or 9 capsules per day)
Trial: 31533750
Drug: Modified SB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified SB (600 mg·kg‐1 over 19.5 h)
Trial: 31533750
Drug: Acute SB
RxNorm normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute SB (300 mg·kg‐1)
Trial: 16116682
Drug: Nebulized fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized fluticasone propionate (FP) 250 mcg twice daily for 10 days
Trial: 16116682
Drug: Nebulized budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nebulized budesonide (BUD) 500 mcg twice daily for 10 days
Trial: 10466475
Drug: Isradipine 2.5
RxNorm normalized name: isradipine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 2.5 mg twice daily (n = 9)
Trial: 10466475
Drug: Metoprolol 50
RxNorm normalized name: metoprolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 50 mg twice daily (n = 8)
Trial: 2192585
Drug: Captopril, 25
RxNorm normalized name: Captopril, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril, 25 mg administered orally
Trial: 526401
Drug: Diazoxide 300
RxNorm normalized name: diazoxide 300 mg/20 mL INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide 300 mg
Trial: 526401
Drug: Labetalol 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 150 mg
Trial: 31000180
Drug: S (‐)
RxNorm normalized name: Esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: S (‐) amlodipine (2.5 mg)